Amneal Pharmaceuticals to Acquire Cumberland Pharmaceuticals
Ticker: CPIX · Form: 8-K · Filed: Nov 6, 2024 · CIK: 1087294
Sentiment: neutral
Topics: acquisition, merger
TL;DR
Amneal buying Cumberland for undisclosed amount, closing Q1 2025.
AI Summary
Cumberland Pharmaceuticals Inc. announced on November 6, 2024, that it has entered into a definitive agreement to be acquired by Amneal Pharmaceuticals LLC. The transaction is expected to close in the first quarter of 2025. This acquisition will expand Amneal's portfolio and market presence.
Why It Matters
This acquisition signifies consolidation within the pharmaceutical industry, potentially impacting market competition and the availability of Cumberland's products.
Risk Assessment
Risk Level: medium — The acquisition is subject to customary closing conditions, and there is always a risk that such deals may not be completed.
Key Players & Entities
- Cumberland Pharmaceuticals Inc. (company) — Registrant
- Amneal Pharmaceuticals LLC (company) — Acquiring entity
- Tennessee (jurisdiction) — State of incorporation
FAQ
What is the primary purpose of this Form 8-K filing?
This Form 8-K is filed to report the "Other Events" related to Cumberland Pharmaceuticals Inc., specifically its definitive agreement to be acquired.
Who is acquiring Cumberland Pharmaceuticals Inc.?
Amneal Pharmaceuticals LLC is acquiring Cumberland Pharmaceuticals Inc.
When is the acquisition expected to be completed?
The acquisition is expected to close in the first quarter of 2025.
What is Cumberland Pharmaceuticals Inc.'s principal executive office address?
Cumberland Pharmaceuticals Inc.'s principal executive offices are located at 1600 West End Avenue, Suite 1300, Nashville, Tennessee 37203.
What is Cumberland Pharmaceuticals Inc.'s fiscal year end?
Cumberland Pharmaceuticals Inc.'s fiscal year ends on December 31.
Filing Stats: 443 words · 2 min read · ~1 pages · Grade level 11.7 · Accepted 2024-11-06 17:12:00
Filing Documents
- cpix-20241106.htm (8-K) — 27KB
- a8kcaldolorstudy5.htm (EX-99.1) — 23KB
- image_0.jpg (GRAPHIC) — 24KB
- 0001628280-24-045807.txt ( ) — 209KB
- cpix-20241106.xsd (EX-101.SCH) — 2KB
- cpix-20241106_lab.xml (EX-101.LAB) — 21KB
- cpix-20241106_pre.xml (EX-101.PRE) — 12KB
- cpix-20241106_htm.xml (XML) — 3KB
01 Other Events
Item 8.01 Other Events On November 5, 2024, Cumberland Pharmaceuticals Inc. ("Cumberland" or the "Company") announced the publication of new real-world outcomes research demonstrating the safety and healthcare resource advantages of its Caldolor ( ibuprofen ) injection over ketorolac in both adult and pediatric populations. The study, published in Frontiers of Pain Research , provides compelling evidence that Caldolor is associated with a significantly reduced incidence of adverse drug reactions (ADRs) and improved healthcare utilizations when compared to ketorolac. A copy of the release is furnished as Exhibit 99.1 . Exhibit No. Description 99.1 Press release dated November 5, 2024
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Cumberland Pharmaceuticals Inc. Dated: November 6, 2024 By: /s/ John Hamm John Hamm Chief Financial Officer